Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.
Overview
Rybelsus® is an oral medication containing semaglutide, a GLP-1 receptor agonist.
Rybelsus® contains semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is the first oral tablet form of this class of medication approved in Canada. Other competing brands containing the same active ingredient but in injectable forms include Ozempic® and Wegovy®. Rybelsus® offers an oral administration route for patients under healthcare supervision.
How rybelsus Works
Semaglutide activates GLP-1 receptors to influence biological pathways.
Semaglutide mimics the naturally occurring hormone GLP-1 that binds to receptors on pancreatic cells and other tissues. This activation influences insulin secretion and other metabolic processes at the cellular level. The oral tablet uses absorption enhancers to enable semaglutide to pass through the gut lining and enter the bloodstream effectively.
Dosage Instructions of rybelsus
: Rybelsus® is available as oral tablets in several strengths.
In Canada, Rybelsus® comes as film-coated tablets in strengths of 3 mg, 7 mg, and 14 mg. Tablets are designed for once-daily oral administration.
Take Rybelsus® tablets once daily on an empty stomach with water.
Patients should take Rybelsus® once daily in the morning, at least 30 minutes before the first food, beverage, or other oral medications. Swallow the tablet whole with a small amount of plain water (not more than 120 mL). Do not chew or crush the tablet to ensure proper absorption. Follow your healthcare provider’s instructions strictly.
Storage Instructions
: Store Rybelsus® tablets in a cool, dry place away from light. Keep Rybelsus® tablets at room temperature between 15°C to 30°C (59°F to 86°F). Protect from moisture and direct sunlight. Keep out of reach of children.
Side Effects of rybelsus
Common mild side effects and rare serious reactions may occur.
Common side effects include nausea, vomiting, diarrhea, decreased appetite, and indigestion. Serious side effects are rare but may include pancreatitis or allergic reactions. Always report unusual symptoms to your healthcare provider promptly.
Important Safety Information About rybelsus
Warnings include risk of thyroid tumors and pancreatitis.
Health Canada-approved warnings highlight that Rybelsus® should not be used by patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Patients should be monitored for signs of pancreatitis and other adverse reactions. Use during pregnancy or breastfeeding should be discussed with a healthcare professional.
Drug Interactions
Certain drugs and substances may affect or be affected by Rybelsus®.
Rybelsus® may interact with oral medications needing rapid absorption and drugs that affect gastrointestinal motility. Use caution with insulin or insulin secretagogues due to hypoglycemia risk. Inform your doctor about all medications, supplements, or herbal products you use.
Brands & DIN Number of rybelsus
Brand Names
- Ozempic®
- Wegovy (for chronic weight management - separate indication)
DIN (Drug Identification Numbers)
02470357
Key Takeaways
- 1• Rybelsus® contains semaglutide, the first oral GLP-1 receptor agonist approved in Canada.
- 2• Available in 3 mg, 7 mg, and 14 mg oral tablets.
- 3• Take once daily on an empty stomach with water.
- 4• Potential side effects include nausea and digestive discomfort; serious risks require medical attention.
- 5• Prescription-only medication with specific Health Canada safety warnings.
- 6• Store tablets in a cool, dry place away from moisture and light.